Literature DB >> 31902371

Selective serotonin reuptake inhibitor 'discontinuation syndrome' or withdrawal.

Ivana Massabki1, Elia Abi-Jaoude2.   

Abstract

Attempts to define selective serotonin reuptake inhibitor (SSRI) withdrawal with the term 'discontinuation syndrome' are not supported by evidence. Acknowledging that SSRI use can result in dependence and withdrawal allows patients to be better informed around decisions related to these drugs, and helps inform strategies for safe tapering as appropriate.

Entities:  

Keywords:  Antianxiety drugs; antidepressants; depressive disorders; drug interactions and side-effects; drugs of dependence disorders

Mesh：

Substances：

Year:  2021        PMID： 31902371     DOI： 10.1192/bjp.2019.269

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN： 0007-1250            Impact factor:   9.319


  5 in total

1.  A Focus on Abuse/Misuse and Withdrawal Issues with Selective Serotonin Reuptake Inhibitors (SSRIs): Analysis of Both the European EMA and the US FAERS Pharmacovigilance Databases.

Authors:  Stefania Chiappini; Rachel Vickers-Smith; Amira Guirguis; John Martin Corkery; Giovanni Martinotti; Fabrizio Schifano
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-01

Review 2.  How effective are antidepressants for depression over the long term? A critical review of relapse prevention trials and the issue of withdrawal confounding.

Authors:  Michael P Hengartner
Journal:  Ther Adv Psychopharmacol       Date:  2020-05-08

3.  The role of Facebook groups in the management and raising of awareness of antidepressant withdrawal: is social media filling the void left by health services?

Authors:  Edward White; John Read; Sherry Julo
Journal:  Ther Adv Psychopharmacol       Date:  2021-01-17

4.  Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum.

Authors:  Michael P Hengartner; Lukas Schulthess; Anders Sorensen; Adele Framer
Journal:  Ther Adv Psychopharmacol       Date:  2020-12-24

5.  Can pragmatic research, real-world data and digital technologies aid the development of psychedelic medicine?

Authors:  Robin L Carhart-Harris; Anne C Wagner; Manish Agrawal; Hannes Kettner; Jerold F Rosenbaum; Adam Gazzaley; David J Nutt; David Erritzoe
Journal:  J Psychopharmacol       Date:  2021-04-22       Impact factor: 4.153
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.